Tested Applications
Positive WB detected in | HepG2 cells, K-562 cells, NCI-H1299 cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:2000 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
27754-1-AP targets C11orf82 in WB, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | C11orf82 fusion protein Ag26829 Predict reactive species |
Full Name | chromosome 11 open reading frame 82 |
Observed Molecular Weight | 120 kDa |
GenBank Accession Number | BC039268 |
Gene Symbol | C11orf82 |
Gene ID (NCBI) | 220042 |
RRID | AB_3669620 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
UNIPROT ID | Q8IXT1 |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
DNA damage-induced apoptosis suppressor (DDIAS) is an oncogenic protein that is highly expressed in several cancers, including colorectal, lung, breast, and hepatocellular carcinoma (HCC), and stimulates cancer cell proliferation and cell cycle progression.DDIAS protects cancer cells from DNA damage reagents and tumor necrosis factor-associated apoptosis-inducing ligands (TRAILs) and positively regulates cancer cell invasion by stabilizing the β- catenin positively regulates cancer cell invasion. Therefore, DDIAS is considered as a potential therapeutic target for malignant lung cancer.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for C11orf82 antibody 27754-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |